Daridorexant, a dual orexin receptor antagonist, is currently approved for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

Daridorexant, Idorsia’s dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related ...

Daridorexant, Idorsia’s dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic ...

Daridorexant, Idorsia's dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia ...

Idorsia Ltd (SIX: IDIA) today announced the publication of "A randomized cross-over trial of daridorexant for the treatment of chronic insomnia and nocturia” in the Journal of Sleep Research. The new ...

Daridorexant is a potential best-in-class treatment in the high-growth, dual orexin antagonist class of medicines treating sleep disorders, such as insomnia Filing of daridorexant in Taiwan ...

The study, named A randomized cross-over trial of daridorexant for the treatment of chronic insomnia and nocturia, is a ...